Sami Hamade

Sami Hamadé joined Aberdare as a Partner in 2006.With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector and has led Aberdare’s efforts in this area. In addition to overseeing the sale of Ablation Frontiers to Medtronic, investments under his current watch include Autonomic Technologies, NxThera, Nevro, Sonitus and VertiFlex. Prior to Aberdare, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant’s venture capital and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) and Spiration Inc (Acquired by Olympus). Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant’s multi-billion dollar leadership position in the stent market. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.